| Primary |
| Infection |
20.0% |
| Lung Infection |
12.0% |
| Pneumonia |
10.0% |
| Mycobacterial Infection |
8.0% |
| Adjuvant Therapy |
6.0% |
| Pyrexia |
6.0% |
| Urinary Tract Infection |
6.0% |
| Klebsiella Infection |
4.0% |
| Sepsis |
4.0% |
| Staphylococcal Sepsis |
4.0% |
| Adverse Event |
2.0% |
| Agranulocytosis |
2.0% |
| Antibiotic Prophylaxis |
2.0% |
| Bacteraemia |
2.0% |
| Bacterial Infection |
2.0% |
| Bacterial Test Positive |
2.0% |
| Burkholderia Pseudomallei Infection |
2.0% |
| Cerebral Infarction |
2.0% |
| Chronic Obstructive Pulmonary Disease |
2.0% |
| Drug Therapy |
2.0% |
|
| Epilepsy |
26.7% |
| Anaphylactic Shock |
6.7% |
| Thrombocytopenia |
6.7% |
| White Blood Cell Count Decreased |
6.7% |
| Adverse Event |
3.3% |
| Anaphylactoid Reaction |
3.3% |
| Blood Creatinine Increased |
3.3% |
| Delirium |
3.3% |
| Dermatitis Allergic |
3.3% |
| Drug Ineffective |
3.3% |
| Dyspnoea |
3.3% |
| Haematuria |
3.3% |
| Haemorrhage |
3.3% |
| Hypersensitivity Vasculitis |
3.3% |
| Loss Of Consciousness |
3.3% |
| Mechanical Ventilation |
3.3% |
| Muscle Spasms |
3.3% |
| Muscle Twitching |
3.3% |
| Neurotoxicity |
3.3% |
| Renal Injury |
3.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
20.5% |
| Product Used For Unknown Indication |
18.8% |
| Pyrexia |
9.7% |
| Acute Myeloid Leukaemia |
7.4% |
| Bronchopulmonary Aspergillosis |
5.2% |
| Pneumonia |
4.9% |
| Antibiotic Therapy |
3.6% |
| Pain |
3.3% |
| Infection |
3.1% |
| Hypertension |
2.8% |
| Device Related Infection |
2.4% |
| Prophylaxis |
2.4% |
| Aplasia |
2.3% |
| Infection Prophylaxis |
2.0% |
| Sepsis |
2.0% |
| Atrial Fibrillation |
1.9% |
| Febrile Infection |
1.9% |
| Colorectal Cancer Metastatic |
1.8% |
| Leukocytosis |
1.8% |
| Perforated Ulcer |
1.8% |
|
| Toxic Skin Eruption |
11.2% |
| Thrombocytopenia |
9.2% |
| Neutropenia |
7.2% |
| Status Epilepticus |
5.9% |
| White Blood Cell Count Decreased |
5.9% |
| Aplastic Anaemia |
5.3% |
| Drug Eruption |
4.6% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
4.6% |
| Pneumonia |
4.6% |
| Stevens-johnson Syndrome |
4.6% |
| Toxic Epidermal Necrolysis |
4.6% |
| Pseudomembranous Colitis |
3.9% |
| Renal Failure Acute |
3.9% |
| Tremor |
3.9% |
| Ventricular Fibrillation |
3.9% |
| Cholestasis |
3.3% |
| Condition Aggravated |
3.3% |
| Cytolytic Hepatitis |
3.3% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.3% |
| Pancytopenia |
3.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
29.8% |
| Product Used For Unknown Indication |
20.9% |
| Prophylaxis |
6.9% |
| Infection |
4.8% |
| Pneumonia |
4.5% |
| Septic Shock |
4.1% |
| Sepsis |
3.5% |
| Pyrexia |
3.1% |
| Stem Cell Transplant |
2.4% |
| Hypertension |
2.2% |
| Infection Prophylaxis |
2.0% |
| Acute Myeloid Leukaemia |
2.0% |
| Hyperthermia |
2.0% |
| Analgesic Therapy |
1.8% |
| Acute Lymphocytic Leukaemia |
1.8% |
| Constipation |
1.7% |
| Pain |
1.7% |
| Fungal Infection |
1.7% |
| Insomnia |
1.7% |
| Febrile Neutropenia |
1.4% |
|
| Thrombocytopenia |
12.1% |
| Pyrexia |
9.6% |
| Septic Shock |
7.5% |
| White Blood Cell Count Decreased |
7.1% |
| Multi-organ Failure |
6.7% |
| Respiratory Failure |
5.4% |
| Rhabdomyolysis |
5.0% |
| Sepsis |
4.6% |
| Vomiting |
4.6% |
| Toxic Skin Eruption |
4.2% |
| Stomatitis |
3.8% |
| Systemic Inflammatory Response Syndrome |
3.8% |
| Toxic Epidermal Necrolysis |
3.8% |
| Death |
3.3% |
| Interstitial Lung Disease |
3.3% |
| Pneumonia |
3.3% |
| Respiratory Distress |
3.3% |
| Hyponatraemia |
2.9% |
| Pulmonary Alveolar Haemorrhage |
2.9% |
| Renal Failure |
2.9% |
|
| Interacting |
| Pneumonia |
33.3% |
| Stent Related Infection |
33.3% |
| Depression |
22.2% |
| Prostate Infection |
11.1% |
|
| Serotonin Syndrome |
50.0% |
| Pyrexia |
25.0% |
| Thrombocytopenia |
25.0% |
|
